JP2019515025A - トポイソメラーゼ毒 - Google Patents

トポイソメラーゼ毒 Download PDF

Info

Publication number
JP2019515025A
JP2019515025A JP2019502543A JP2019502543A JP2019515025A JP 2019515025 A JP2019515025 A JP 2019515025A JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019515025 A JP2019515025 A JP 2019515025A
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515025A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ. ラヴォア,エドモンド
ジェイ. ラヴォア,エドモンド
ケー. パーヒ,アジット
ケー. パーヒ,アジット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Rutgers, The State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University of New Jersey filed Critical Rutgers, The State University of New Jersey
Publication of JP2019515025A publication Critical patent/JP2019515025A/ja
Publication of JP2019515025A5 publication Critical patent/JP2019515025A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2019502543A 2016-04-04 2017-04-03 トポイソメラーゼ毒 Pending JP2019515025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318139P 2016-04-04 2016-04-04
US62/318,139 2016-04-04
PCT/US2017/025779 WO2017176648A1 (en) 2016-04-04 2017-04-03 Topoisomerase poisons

Publications (2)

Publication Number Publication Date
JP2019515025A true JP2019515025A (ja) 2019-06-06
JP2019515025A5 JP2019515025A5 (cg-RX-API-DMAC7.html) 2020-05-14

Family

ID=60000629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019502543A Pending JP2019515025A (ja) 2016-04-04 2017-04-03 トポイソメラーゼ毒

Country Status (6)

Country Link
US (1) US11091498B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442979A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019515025A (cg-RX-API-DMAC7.html)
CN (1) CN109219610A (cg-RX-API-DMAC7.html)
CA (1) CA3019945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017176648A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824771B (zh) * 2019-03-07 2020-06-30 中国药科大学 一种降糖肽及其应用
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065448A2 (en) * 2004-11-18 2006-06-22 Threshold Pharmaceuticals, Inc. Topoisomerase inhibitors and prodrugs
JP2007514652A (ja) * 2003-11-06 2007-06-07 シアトル ジェネティックス, インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
JP2010519310A (ja) * 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
JP2010526821A (ja) * 2007-05-08 2010-08-05 ジェネンテック, インコーポレイテッド システイン改変抗muc16抗体および抗体−薬物結合体
WO2010127363A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2014164503A1 (en) * 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides
JP2015516401A (ja) * 2012-04-24 2015-06-11 シアトル ジェネティックス, インコーポレイテッド Dr5リガンド薬物コンジュゲート
JP2015521187A (ja) * 2012-05-15 2015-07-27 シアトル ジェネティクス,インコーポレイティド 自己安定化リンカー結合体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) 1961-04-25 Acridine derivatives
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420045A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
US3267107A (en) 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (cg-RX-API-DMAC7.html) 1972-08-25 1974-04-22
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US4980344A (en) 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd 13−プロピルベルベリンの塩
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE69430752T2 (de) 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Tetracyclische verbindungen
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
CA2221248A1 (en) 1995-05-17 1996-11-21 Leroy Fong Liu Tribenzimidazoles useful as topoisomerase i inhibitors
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
PL328402A1 (en) 1996-02-12 1999-01-18 Rutgers Analoques of coralline as inhibitors of topoisomerase
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
BR9711296A (pt) 1996-09-23 1999-08-17 Univ Rutgers Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2000021537A1 (en) 1998-10-14 2000-04-20 Purdue Research Foundation Novel indenoisoquinolines as antineoplastic agents
WO2001032631A2 (en) 1999-10-29 2001-05-10 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
CA2467279A1 (en) 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
DE60225943T2 (de) 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
ATE405568T1 (de) 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
AU2002363658B2 (en) 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
US6989387B2 (en) 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003268075A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003290818A1 (en) 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ[i]フェナントリジン誘導体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514652A (ja) * 2003-11-06 2007-06-07 シアトル ジェネティックス, インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
WO2006065448A2 (en) * 2004-11-18 2006-06-22 Threshold Pharmaceuticals, Inc. Topoisomerase inhibitors and prodrugs
JP2010519310A (ja) * 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
JP2010526821A (ja) * 2007-05-08 2010-08-05 ジェネンテック, インコーポレイテッド システイン改変抗muc16抗体および抗体−薬物結合体
WO2010127363A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
JP2015516401A (ja) * 2012-04-24 2015-06-11 シアトル ジェネティックス, インコーポレイテッド Dr5リガンド薬物コンジュゲート
JP2015521187A (ja) * 2012-05-15 2015-07-27 シアトル ジェネティクス,インコーポレイティド 自己安定化リンカー結合体
WO2014164503A1 (en) * 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides

Also Published As

Publication number Publication date
EP3442979A4 (en) 2019-12-18
WO2017176648A1 (en) 2017-10-12
EP3442979A1 (en) 2019-02-20
CN109219610A (zh) 2019-01-15
US20200325149A1 (en) 2020-10-15
CA3019945A1 (en) 2017-10-12
US11091498B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
US11497757B2 (en) Silanol based therapeutic payloads
JP6824931B2 (ja) 第3級アミン含有薬物物質の標的送達
EP0673258B1 (en) Polymer-bound camptothecin derivatives
US20090246211A1 (en) Molecular constructs suitable for targeted conjugates
CA3099421A1 (en) Compounds comprising a linker for increasing transcyclooctene stability
JP2018507844A (ja) 抗体薬物コンジュゲート
KR20250150111A (ko) 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도
CA3210473A1 (en) Branched linkers for antibody-drug conjugates and methods of use thereof
US12343399B2 (en) Polymer linkers and their uses
AU2012275953B2 (en) Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
EP2740493A1 (en) Conjugates of the B-subunit of Shiga toxin for anticancer therapies
US11091498B2 (en) Topoisomerase poisons
US9321781B2 (en) Topoisomerase inhibitors
KR102346268B1 (ko) 경구 항암 전구약물을 포함하는 복합체, 이의 제조방법 및 이의 용도
EP4674840A1 (en) Chemical coupling linker and use thereof
CA3026434C (en) Polymer linkers and their uses
KR20250125737A (ko) 항체-약물 접합체에 사용하기 위한 신규 약물-링커 화합물
KR20240016231A (ko) 신규 오리스타틴 전구약물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102